Skip to content
lifestyle.brickvest.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
Dianthus Therapeutics, Inc.
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 24, 2026
Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 20, 2026
Dianthus Therapeutics, Inc. Announces Proposed $400 Million Underwritten Public Offering
May 18, 2026
Dianthus Therapeutics Announces Early GO Decision Following Interim Responder Analysis in Phase 3 CAPTIVATE Trial of Claseprubart in Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
May 18, 2026
Dianthus Therapeutics, Inc. Announces Closing of its Upsized $719 Million Underwritten Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
May 16, 2026
Dianthus Therapeutics, Inc. Announces Pricing of Upsized $625 Million Underwritten Public Offering
May 16, 2026
←
Previous Page
1
2